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DISCUSSION
Dr Quinones-Baldrich (Los Angeles, Calif). I would like to
congratulate Dr Brown and the vascular service at Northwestern
University for an excellent presentation of their 7-year experience
with endovascular repair of complex thoracic aortic pathology.
They have treated 111 high-risk patients with either complete
endovascular or a hybrid alternative to surgical repair. Some of
these interventions were not really minimally invasive. It is really a
new day in vascular surgery when we call an aortic debranching or
an elephant trunk part of a minimally invasive approach. They do
represent an option to what is otherwise a formidable operative
intervention. Although a comparison to standard surgical repair is
not really appropriate, the overall results support their conclusion
that endovascular repair of complex aortic pathology is a viable
alternative in the management of these difficult patients. As an
advocate of endovascular treatment to these complex cases, I
remain concerned that the overall results are not a significant
improvement over those accomplished by experienced surgeons
performing open repair.
A combined stroke and paraplegia incidence of about 12%
must be reduced if we are to continue to offer endovascular repair
as a better alternative. Keep in mind that their series includes
patients with penetrating aortic ulcer, intramural hematoma, trau-
matic injuries, and other pathology in which the risk of these
complications is relatively low for open surgical repair. Spinal
catheter drainage was used in 17 patients. In several of these
patients the indication for spinal drainage was related to the
extensive coverage of the descending thoracic aorta. In the rest, the
indication was previously aortic surgery. There were 38 patients in
their series that had prior aortic surgery, which leads to my first
question: why was spinal catheter drainage not used in all patients
with prior aortic surgery? What was the incidence of paraplegia in
those patients with prior aortic surgery in whom spinal catheter
drainage was not used?
The 30-day mortality of 5.4% as reported in this series is
excellent, particularly when one considers that only about half of
the cases were performed electively. On the other hand, the late
mortality, which the authors report represents the 1-year mortality
as delineated in the manuscript, was about 23% as calculated by
nonactuarial methods. This is of concern. I have attempted to
calculate their cumulative mortality based on the information in
the manuscript, and by my estimate, the 1-year cumulative mor-
tality approaches 30%. This does not take into account the addi-
tional interventions and other complications that required treat-
ment. Keep in mind that a high 1-year mortality tends to improve
the calculation of incidence of nonfatal events because survivors
tend to have fewer of these events. Their follow-up ranges from 1
to 78 months, which leads to my next question: have the authors
calculated actuarial survival for their entire series? What is the
1-year mortality as calculated by these actuarial methods?
Early and mid-term endograft infection was uniformly lethal.
The authors have attempted to identify factors that would increase
the risk of infection as a complication. Could the authors tell us
which risk factors or findings on imaging they consider a contra-
indication for endovascular repair?
Several patients in their series underwent successful open
surgical repair after a failed endovascular approach, which leads me
to my final question: do the authors recommend primary open
repair in certain cases? What are their criteria to recommend open
repair as opposed to an endovascular treatment?
I would like to thank the society for the privilege of discussing
this excellent experience and the authors for providing me with a
copy of the manuscript prior to the meeting.
Dr Brown. Thank you again to the society for allowing us the
opportunity to present our results for the treatment of thoracic
aortic pathology. Many thanks as well to Dr Quinones for review-
ing the manuscript and putting forth these excellent questions.
Our 30-day mortality rate of 5.4% is comparable to other
reports for the endovascular treatment of thoracic aortic disease;
however, it is true that we did see a high rate of death in our series
within 1 year of their index procedure. The cause of death was
related to the patient’s comorbidities or graft infection. We treated
a high-risk group of patients with various types of thoracic aortic
pathology. Those patients who were not part of an industry-
sponsored trial were treated even though they may have had a
limited life expectancy from other disease states. We managed
these patients based upon the supposition that we could treat their
thoracic aortic pathology in a less morbid manner than we could
with open surgery. What is evident is that patients with thoracic
aortic disease, especially those in need of an emergency operation,
are amongst the highest risk patients that we care for. Even a
minimally invasive operation is not without significant risks. We
will include in ourmanuscript an analysis of our survival in the form
of a life table.
With regards to our stroke rate, we acknowledge that 9% is,
indeed, a high number when compared to other published series.
We looked at the relationship of stroke to type of device deployed
and also to the patient’s cerebral artery anatomy. We found a
higher incidence of stroke in patients in which a custom-made graft
was deployed. The large and inflexible delivery systems required for
custom-made graft deployment cause excessive manipulation of
the aortic arch, which may result in more embolic events from
disruption of aortic atherosclerotic plaque and debris. This is
supported by other reports that have noted similar rates of stroke
when custom-made grafts are used. In our patients in whom the
less bulky industry-designed devices were placed, our stroke rate
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was only 2.9%. We also found, not unexpectedly, that when
patients had coverage of a left subclavian artery that gave origin to
dominant left vertebral artery, strokes occurred. We now routinely
transpose or bypass the left subclavian artery in almost all of our
patients prior to intentional coverage, but especially in patients
with a dominant left vertebral artery. This approach has resulted in
a decrease in the incidence of posterior circulation stroke. As
technology continues to improve we predict the incidence of
stroke may decrease further.
In terms of paralysis, our results are on par with other reports
of endovascular thoracic aortic repair. We put in spinal drains in
approximately 16% of our patients. It is true that 34% of our
patients had previous aortic surgery. The decision to place drains
was based on surgeon preference and also depended on the emer-
gency nature of the operation. Even though we do not use a
standard algorithm for placement of spinal drains, we have turned
toward placing prophylactic spinal drains in those patients in which
extensive intercostal artery coverage is anticipated and/or in the
patient with compromised pelvic and lumbar arterial flow from
previous aortic repair. In the latter half of our series, spinal drains
were placed more frequently than in the beginning of our experi-
ence.
To address your question about predicting endograft infec-
tion, we are still trying to sort this one out. Four out of the six
patients who developed delayed infection had endovascular aortic
repair under emergency conditions such as rupture or acute expan-
sion with pain. In our series of patients, there were no clear-cut
imaging findings that indicated primary aortic infection. In one
patient, we did suspect an underlying remote infection from a prior
open intervention that was present at the time of deployment. The
remaining patients either had presumed device seeding from sys-
temic infections that developed later or had unknown underlying
primary aortic infections, which was what brought them to emer-
gency repair in the first place. We caution against the use of these
grafts in the face of a known infection since our experience has
shown that delayed endograft infection is a highly morbid condi-
tion and in our series led to death, rupture, and/or type I endoleak
in all cases. We administer antibiotic prophylaxis before every case
and aggressively treat any postoperative infection in order to
prevent possible delayed seeding of the endograft.
To address the final question regarding criteria for open repair
vs endovascular repair, we choose the operation that is bet suited
for the patient’s anatomy and clinical condition. Patients with
anatomy suitable for treatment with an endograft and who were
also considered relatively high risk for open repair were more likely
to undergo endovascular repair. We concede that one of the
limitations of this paper is the fact that we do not have an open
surgical patient group for comparison. Many of our degenerative
aneurysm patients were treated as part of a clinical trial, while other
patients with other pathologies were treated with a minimally
invasive approach because they were not thought to be candidates
for open conventional repair either due to medical comorbidities
or due to the clinical situation.
While there certainly are limits to the benefit gained with the
endovascular management of thoracic aortic pathology and even
though many patients require secondary interventions, the endo-
vascular treatment of thoracic aortic pathology is efficacious and
has decreased perioperative morbidity and mortality when com-
pared to open surgical repair, especially in high-risk patients.
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